At the time of writing, CareDx Inc [CDNA] stock is trading at $17.61, up 12.45%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The CDNA shares have gain 15.86% over the last week, with a monthly amount glided 58.65%, and seem to be holding up well over a long-time horizon.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
On 26, January 2023, JACC Publication Guides Use of CareDx’s HeartCare Transplant Rejection Surveillance in Clinical Practice. In a post published today on Yahoo Finance, Guide Helps Transplant Centers Continue the Evolution from Endomyocardial Biopsies to Noninvasive Surveillance Using AlloMap GEP and AlloSure dd-cfDNA.
From an analyst’s perspective:
CareDx Inc [NASDAQ: CDNA] stock has seen the most recent analyst activity on April 25, 2022, when Stephens initiated its Overweight rating and assigned the stock a price target of $50. On June 03, 2021, Goldman initiated with a Buy rating and assigned a price target of $95 on the stock. H.C. Wainwright downgraded its rating to a Neutral. H.C. Wainwright reiterated its recommendation of a Buy and raised its price target to $55 on October 30, 2020. H.C. Wainwright reiterated a Buy rating for this stock on October 08, 2020, and upped its price target to $47. In a note dated October 02, 2020, H.C. Wainwright reiterated an Buy rating on this stock and boosted its target price from $40 to $45.
For the past year, the stock price of CareDx Inc fluctuated between $10.50 and $46.88. Currently, Wall Street analysts expect the stock to reach $28.00 within the next 12 months. CareDx Inc [NASDAQ: CDNA] shares were valued at $17.61 at the most recent close of the market. An investor can expect a potential return of 59.0% based on the average CDNA price forecast.
Analyzing the CDNA fundamentals
According to CareDx Inc [NASDAQ:CDNA], the company’s sales were 79.36 billion in the recent quarter, which represents an 5.00% jump. Gross Margin for this corporation currently stands at +66.60% with Operating Margin at -9.93%, Pretax Margin comes in at -10.83%, and Net Margin reading is -10.34%.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 16.63 points at the first support level, and at 15.64 for the second support level. However, for the 1st resistance point, the stock is sitting at 18.32, and for the 2nd resistance point, it is at 19.02.
CareDx Inc [CDNA] reported earnings per share of -$0.13 for its fiscal quarter that ended on 6/29/2022. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.11/share, meaning a difference of -$0.02 and a surprise factor of -18.20%. By comparison, the stated earnings for the previous quarter ended on 3/30/2022 were -$0.13 per share as compared to estimates of -$0.05 per share, a difference of -$0.08 representing a surprise of -160.00%.
Ratios To Look Out For
It is important to note that CareDx Inc [NASDAQ:CDNA] has a current ratio of 5.50. Also, the Quick Ratio is 5.38, while the Cash Ratio stands at 4.51. Considering the valuation of this stock, the price to sales ratio is 8.02, the price to book ratio is 5.17.
Transactions by insiders
We now turn our attention to insider trading, which in the past 3 months has resulted in 6 insider buyings of 21,791 shares and 1 insider sellings of 8,516 shares. Recent insider trading involved Seeto Reginald, that happened on Jan 03 when 2818.0 shares were sold. Director, Maag Peter completed a deal on Aug 11 to sell 20000.0 shares. Meanwhile, Director Colon Grace sold 2521.0 shares on Aug 10.